Drug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

OBJECTIVES: To assess the effects of interventions authorised by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) for prevention of COVID-19 progression to severe disease in outpatients. SETTING: Outpatient treatment. PARTICIPANTS: Participants with a diagnosis of COV...

Descripción completa

Detalles Bibliográficos
Autores principales: Petersen, Johanne Juul, Jørgensen, Caroline Kamp, Faltermeier, Pascal, Siddiqui, Faiza, Feinberg, Joshua, Nielsen, Emil Eik, Torp Kristensen, Andreas, Juul, Sophie, Holgersson, Johan, Nielsen, Niklas, Bentzer, Peter, Thabane, Lehana, Kwasi Korang, Steven, Klingenberg, Sarah, Gluud, Christian, Jakobsen, Janus C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314423/
https://www.ncbi.nlm.nih.gov/pubmed/37339844
http://dx.doi.org/10.1136/bmjopen-2022-064498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314423/
https://www.ncbi.nlm.nih.gov/pubmed/37339844
http://dx.doi.org/10.1136/bmjopen-2022-064498

Ejemplares similares